Every 8-K that Generate Biomedicines, Inc. (GENB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow GENB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GENB filings page.
Generate Biomedicines, Inc. (GENB) reports that draft versions of three scientific posters on its antibody GB-0895 were inadvertently made publicly available on the European Respiratory Society (ERS) website before the expected embargo expiry. As a precaution, the company is furnishing the final posters, which summarize Phase 1 and Phase 3 program details, as an exhibit.
The Phase 1 asthma study (GB-0895-101) tests single and multiple subcutaneous doses in mild-to-moderate asthma. GB-0895 was generally well tolerated, with no treatment-related serious adverse events, a sustained, dose-proportional pharmacokinetic profile, and an estimated ~98‑day half‑life at 300 mg. Marked and durable reductions in key inflammatory biomarkers (BEC, FeNO, IL‑5, IL‑13) were observed for at least six months, with 300 mg achieving maximal biomarker suppression.
In COPD participants, single-dose GB-0895 (300 mg and 600 mg) also showed a tolerability profile with no treatment-related serious adverse events and sustained biomarker reductions for at least six months. GB-0895 is now being evaluated in two ongoing, global, randomized, double-blind, placebo-controlled Phase 3 trials, SOLAIRIA‑1 and SOLAIRIA‑2, in adults and adolescents with severe uncontrolled asthma.
Generate Biomedicines, Inc. reported Q2 2026 results and a business update. Collaboration revenue was $6.3 million and the company recorded a net loss of $67.3 million, reflecting higher research and development spending. Cash, cash equivalents, and marketable securities totaled $457.4 million as of June 30, 2026, and management believes this will fund the operating plan into the first half of 2028.
The pipeline advanced with global Phase 3 SOLAIRIA-1 and SOLAIRIA-2 studies of GB-0895 in severe asthma progressing, including regulatory approvals in 33 of a planned 42 countries and recruitment underway across six global regions. Phase 1b GB-0895 COPD data and additional asthma data will be presented at the ERS Congress 2026.
In oncology, all patients were enrolled in the first cohort of the Phase 1 study of GB-4362, which has FDA Fast Track designation, and a trial-in-progress poster is expected at ESMO 2026. A Novartis collaboration asset designed with the Generate Platform advanced into the partner’s preclinical pipeline, and a Phase 1 trial of GB-5267 CAR T in ovarian cancer is now recruiting.
Generate Biomedicines, Inc. reported first quarter 2026 results, combining a recent IPO cash infusion with higher investment in its pipeline. Cash, cash equivalents, and marketable securities were $516.6 million as of March 31, 2026, reflecting $369.3 million in net IPO proceeds and supporting an expected cash runway into the first half of 2028.
Collaboration revenue for the quarter was $7.2 million, while research and development expenses rose to $57.8 million and general and administrative expenses to $13.5 million, driven partly by Phase 3 work on GB-0895 and public-company costs. Net loss attributable to common stockholders widened to $69.2 million, and net cash used in operating activities was $80.4 million for the quarter.
The company highlighted continued advancement of its generative biology platform and clinical programs, including Phase 3 trials of GB-0895 in severe asthma, ongoing development in COPD, and oncology programs GB-4362 and GB-5267, with GB-4362 holding FDA Fast Track designation.
Generate Biomedicines, Inc. has overhauled its corporate charter and bylaws in connection with completing its initial public offering. The company filed an amended and restated certificate of incorporation in Delaware that authorizes 500,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock and removes references to prior preferred series.
The new charter also removes stockholders’ ability to act by written consent or to call special meetings, centralizing these corporate actions in formal meeting processes. Updated bylaws establish detailed procedures for stockholder meetings, add advance notice requirements for proposals and director nominations, and align with the revised charter provisions.